



上海復旦張江生物醫藥股份有限公司

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China)

(Stock code: 8231)

FORMS RELATING TO LISTING

Form F

The Growth Enterprise Market (GEM)

Company Information Sheet

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this information sheet, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this information sheet.

Company name : Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd.

Stock code (ordinary shares): 8231

This information sheet contains certain particulars concerning the above company (the "Company") which is listed on the Growth Enterprise Market ("GEM") of the Stock Exchange of Hong Kong Limited (the "Exchange"). These particulars are provided for the purpose of giving information to the public with regard to the Company in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the "GEM Listing Rules"). They will be displayed at the GEM website on the Internet. This information sheet does not purport to be a complete summary of information relevant to the Company and/or its securities.

The information in this sheet was updated as of **30 May 2013**.

A. General

Place of incorporation : **The People's Republic of China**

Date of initial listing on GEM : **13 August 2002**

Name of Sponsor(s) : **Guotai Junan Capital Limited**

Names of directors :

Executive Directors: **Mr. Wang Hai Bo**
Mr. Su Yong
Mr. Zhao Da Jun

Non-executive Directors: **Ms. Fang Jing**
Ms. Ke Ying
Mr. Shen Bo
Ms. Yu Xiao Yang

Independent Non-executive Directors: **Mr. Pan Fei**
Mr. Cheng Lin
Mr. Weng De Zhang
Mr. Zhou Zhong Hui

Name(s) of substantial shareholder(s)
(as such term is defined in rule 1.01 of the
GEM Listing Rules) and their respective
interests in the ordinary shares and other
securities of the Company :

Name	Number of shares held upon completion of the placing	Approximate percentage in total share capital of the Company upon completion of the placing
Shanghai Pharmaceutical Holding Co. Ltd.	210,142,560	24.66%
China New Enterprise Investment Fund II	130,977,816	15.37%
Shanghai Zhangjiang Hi-Tech Park Development Co. Ltd.	105,915,096	12.43%

Name(s) of company(ies) listed on GEM
or the Main Board of the Stock Exchange
within the same group as the Company : **N/A**

Financial year end date : **31 December**

Registered address : **No. 308 Cailun Road**
Zhangjiang Hi-Tech Park
Pudong
Shanghai
The PRC (PC:201210)

Head office and principal
place of business : **15th Floor, The Bank of East Asia Building**
10 Des Voeux Road Central
Central
Hong Kong

Web-site address (if applicable) : **www.fd-zj.com**

Share registrar : **Computershare Hong Kong Investor Services Limited**
46th Floor Hopewell Centre
183 Queen's Road East
Wanchai
Hong Kong

Auditors : **PricewaterhouseCoopers**
22nd Floor, Prince's Building
Central
Hong Kong

B. Business activities

The Company is a bio-pharmaceutical company that is principally engaged in the R&D manufacture and sales of new drugs with patents or specific drugs, and provision of auxiliary service.

C. Ordinary shares

Number of ordinary shares in issue : **512,000,000 Domestic Shares and 340,000,000 H Shares**

Par value of ordinary shares in issue : **RMB0.10**

Board lot size (in number of shares) : **4,000**

Name of other stock exchange(s) on which ordinary shares are also listed : **N/A**

D. Warrants

Stock code : **N/A**

Board lot size : **N/A**

Expiry date : **N/A**

Exercise price : **N/A**

Conversion ratio : **N/A**
(Not applicable if the warrant is denominated in dollar value of conversion right)

No. of warrants outstanding : **N/A**

No. of shares falling to be issued upon the exercise of outstanding warrants : **N/A**

E. Other securities

Details of any other securities in issue.
(i.e. other than the ordinary shares described in C above and warrants described in D above but including options granted to executives and/or employees).

(Please include details of stock code if listed on GEM or the Main Board or the name of any other stock exchange(s) on which such securities are listed).

If there are any debt securities in issue that are guaranteed, please indicate name of guarantor.

N/A

Responsibility statement

The directors of the Company (the "Directors") as at the date hereof hereby collectively and individually accept full responsibility for the accuracy of the information contained in this information sheet ("the Information") and confirm, having made all reasonable inquiries, that to the best of their knowledge and belief the Information is accurate and complete in all material respects and not misleading and that there are no other matters the omission of which would make any Information inaccurate or misleading.

The Directors also collectively and individually accept full responsibility for submitting a revised information sheet, as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.

The Directors acknowledge that the Stock Exchange has no responsibility whatsoever with regard to the Information and undertake to indemnify the Exchange against all liability incurred and all losses suffered by the Exchange in connection with or relating to the Information.

Signed:

Wang Hai Bo

Su Yong

Zhao Da Jun

Fang Jing

Ke Ying

Shen Bo

Yu Xiao Yang

Pan Fei

Cheng Lin

Weng De Zhang

Zhou Zhong Hui